Get the Stockscreener App
0.1899
5.05%
-0.0101
After Hours:
.19
0.000100
+0.05%
Calidi Biotherapeutics Inc stock is traded at $0.1899, with a volume of 3.51M.
It is down -5.05% in the last 24 hours and down -29.43% over the past month.
Calidi Biotherapeutics Inc., a clinical stage immuno-oncology company, engages in developing immunotherapies for the treatment of cancer. It engages in advancing a potent allogeneic stem cell capable of carrying an anti-tumor payload for use in multiple oncology indications, including high-grade gliomas and solid tumors. The company's cell-based delivery platforms are designed to protect, amplify, and potentiate oncolytic viruses leading to enhanced efficacy and improved patient safety. Its pipeline of products candidates in the clinic includes NeuroNova that are allogeneic neural stem cells loaded with an oncolytic adenovirus for the treatment of high-grade gliomas; and SuperNova, which are allogeneic adipose-derived mesenchymal stem cells loaded with tumor-selective CAL1 oncolytic vaccinia virus for the treatment of advanced metastatic solid tumors. The company was founded in 2014 and is headquartered in San Diego, California.
See More
Previous Close:
$0.20
Open:
$0.197
24h Volume:
3.51M
Relative Volume:
0.99
Market Cap:
$2.89M
Revenue:
-
Net Income/Loss:
$-25.74M
P/E Ratio:
-0.0385
EPS:
-4.938
Net Cash Flow:
$-21.41M
1W Performance:
-12.29%
1M Performance:
-29.43%
6M Performance:
-87.34%
1Y Performance:
-96.04%
1-Day Range:
$0.1862
$0.205
1-Week Range:
$0.1775
$0.2105
52-Week Range:
$0.1775
$19.20
Calidi Biotherapeutics Inc Stock (CLDI) Company Profile
Name
Calidi Biotherapeutics Inc
Sector
Industry
Phone
(858) 794-9600
Address
4475 Executive Drive, Suite 200, San Diego
Compare CLDI vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CLDI
Calidi Biotherapeutics Inc
|
0.1899 | 3.05M | 0 | -25.74M | -21.41M | -4.938 |
VRTX
Vertex Pharmaceuticals Inc
|
450.41 | 114.99B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
712.87 | 75.47B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
822.13 | 49.92B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
293.45 | 38.92B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
149.47 | 31.88B | 742.00K | -1.37B | -1.07B | -7.0731 |
Calidi Biotherapeutics Inc Stock (CLDI) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-22-23 | Initiated | H.C. Wainwright | Buy |
| Oct-09-23 | Initiated | Robert W. Baird | Outperform |
Calidi Biotherapeutics Inc Stock (CLDI) Latest News
Calidi Highlights Q1 Results and RedTail Platform Progress - TipRanks
Calidi Biotherapeutics 1Q 2026: Net loss $4.42M, EPS $(0.43) — 10-Q Summary - TradingView
Calidi Biotherapeutics (CLDI) Q1 2026 loss, cash runway and warrant overhang detailed - Stock Titan
Calidi Biotherapeutics (NYSE: CLDI) Q1 2026 loss narrows as cash rises - Stock Titan
Biotech Calidi cuts costs, taps AI partner for CLD-401 IND - Stock Titan
Calidi Biotherapeutics Reports First Quarter 2026 Financial Results and Recent Operational Highlights - GlobeNewswire
Calidi Biotherapeutics Confirms Featured Speaker Presentation Tomorrow at the ASGCT Conference in Boston - Yahoo Finance
TradingKey - TradingKey
How Calidi (CLDI) maintains its competitive edge | Q4 2025: Better Than ExpectedFree Cash Margin - newser.com
Calidi Biotherapeutics, Inc. Files Form 8-K for Material Definitive Agreement and Common Stock Purchase Warrants – SEC Filing May 6, 2026 - Minichart
Calidi Biotherapeutics Issues Private Placement Warrant Financing - TipRanks
Calidi Biotherapeutics Issues Warrant for 17.4M Shares, Linked to Up to $4M Stock Buys at $0.23 - TradingView
Calidi Biotherapeutics (CLDI) grants 17.4M-share warrant linked to $4M equity - Stock Titan
CLDI Stock Price, Quote & Chart | CALIDI BIOTHERAPEUTICS INC (NYSEARCA:CLDI) - ChartMill
Calidi Biotherapeutics announces underwritten public offering - Investing.com
DEFA14A: Others - Moomoo
Calidi Biotherapeutics (CLDI) sets vote on reverse split and larger equity plan - Stock Titan
Calidi Biotherapeutics announces strategic partnership with Transferai - marketscreener.com
Calidi partners with TransferAI for CLD-401 regulatory filing By Investing.com - Investing.com South Africa
Calidi partners with TransferAI for CLD-401 regulatory filing - Investing.com
Calidi Biotherapeutics Announces Strategic Partnership With Transferai - TradingView
Calidi turns to AI software as it pushes CLD-401 toward filing - Stock Titan
Calidi (CLDI) Stock: Breakout Potential Analysis | Q4 2025: Better Than ExpectedVerified Stock Signals - Cổng thông tin điện tử tỉnh Lào Cai
CLDI (Calidi Biotherapeutics Inc.) posts 73.6% positive Q4 2025 EPS surprise, shares edge slightly lower in today’s trading.Revenue Diversification - Cổng thông tin điện tử tỉnh Lào Cai
Calidi Biotherapeutics Presents New Data on Its Lead Asset CLD-401 at the AACR Annual Meeting in April 2026 - marketscreener.com
Calidi says CLD-401 drove tumor immune response ahead of 2026 IND - Stock Titan
Calidi presents cancer therapy data at AACR meeting By Investing.com - Investing.com India
Certain Stock Options of Calidi Biotherapeutics, Inc. are subject to a Lock-Up Agreement Ending on 21-APR-2026. - marketscreener.com
Calidi (CLDI) Stock Futures Trade (Trend Weakens) 2026-04-20Price Target - Cổng thông tin điện tử tỉnh Lào Cai
Calidi presents cancer therapy data at AACR meeting - Investing.com
Calidi Biotherapeutics Presents New Data on Its Differentiated Approach to In Situ T-Cell Engagers Including a New Candidate Targeting TROP-2 at the AACR Annual Meeting in April 2026 - The Manila Times
Calidi targets a hard cancer marker with tumor-restricted engager - Stock Titan
Calidi Biotherapeutics (CLDI) seeks approval for reverse split, 1.95M-plan increase - Stock Titan
Calidi Biotherapeutics Streamlines Board, Enhances Audit Oversight - TipRanks
Calidi Biotherapeutics Announces Participation in RedChip’s April 16 Virtual Investor Conference to Feature Companies Advancing Clinical Pipelines and Scalable Healthcare Platforms - Sahm
Calidi Biotherapeutics to Showcase Advances in Virotherapy at RedChip's Virtual Investor Conference on April 16, 2026 - Quiver Quantitative
Calidi Biotherapeutics Announces Participation in RedChip’s April 16 Virtual Investor ... - Caledonian Record
Calidi Biotherapeutics Announces Participation in RedChip’s - GlobeNewswire
Calidi to present RedTail platform data at Iceland conference By Investing.com - Investing.com Australia
Calidi to present RedTail platform data at Iceland conference - Investing.com
Calidi Biotherapeutics Announces Speaker Presentation at IOVC Conference in Reykjavík, Iceland on April 28th Highlighting the RedTail Platform’s Ability to Deliver Genetic Medicines to Distal Sites of Disease with Systemic Therapy - The Manila Times
Cancer virus therapy data from Calidi heads to Iceland conference - Stock Titan
Fed Watch: Does Calidi Biotherapeutics Inc have pricing powerFed Meeting & AI Based Buy and Sell Signals - baoquankhu1.vn
Aug Summary: How volatile is Cellectar Biosciences Inc stock2026 Spike Watch & Daily Entry Point Trade Alerts - baoquankhu1.vn
Does Calidi Biotherapeutics Inc have pricing power2026 Price Swings & Low Risk High Reward Trade Ideas - baoquankhu1.vn
Calidi Biotherapeutics (CLDI) Stock Analysis Report | Financials & Insights - Benzinga España
Calidi Biotherapeutics Inc Stock (CLDI) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.96%
0.26%
Cap:
|
Volume (24h):